---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-003753"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2025-02-04T23:59:59+00:00"
generated_at: "2026-05-27T03:18:48.598537+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cumberland Pharma Phase 2 ifetroban trial meets primary endpoint in DMD heart disease

## Summary
- High-dose ifetroban (300mg/day) produced 3.3% LVEF improvement vs placebo decline of 1.5%, net 4.8% benefit.
- Comparison with propensity-matched natural history controls showed 5.4% overall LVEF improvement in high-dose group.
- Both doses were well-tolerated; no serious drug-related events reported among 41 enrolled DMD patients.
- Ifetroban holds FDA Orphan Drug and Rare Pediatric Disease Designations; first Phase 2 study for DMD heart disease.
- Company plans end of Phase 2 FDA meeting to discuss development path; potential first therapy for DMD cardiomyopathy.

## SEC filing metadata
- accession: 0001628280-25-003753
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2025-02-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000162828025003753/0001628280-25-003753-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000162828025003753/cpix-20250204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-003753
- JSON: https://secwatch.observer/filing/0001628280-25-003753.json
- Plain text: https://secwatch.observer/filing/0001628280-25-003753.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.